- About Us
- Nano-Social Network
- Nano Consulting
- My Account
BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results on its new biotherapy, plasmid AMEPô, for metastatic melanoma treatment at the at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009.
Worldwide melanoma incidence is about 140 000 per year with a high frequency especially in Australia, North America and Europe. When treated at early stage, the prognosis of local melanoma is excellent and associated with a prolonged survival. Nevertheless, the five-year survival rate of advanced or metastatic cancers is low, between 5 and 25% according to the stage and localisation of the disease. No treatments or treatment strategies are demonstrated to be consistently effective in these advanced melanoma patients. Recommendations from all medical and scientific cancer and dermatology societies are thus to evaluate new treatments.
BioAlliance Pharma develops a new biotherapy, plasmid AMEPô, which displays anti-angiogenic and anti-metastatic properties. AMEPô binds αvβ3 and α5β1 integrins which are receptors overexpressed by tumoral melanocytes and also activated endothelial cells involved in new blood vessel formation.
Results presented during the AACR annual meeting describe these anti-angiogenic and anti-tumoral properties of the plasmid AMEPô biotherapy in in vitro and in vivo models. In an in vivo experimental model of invasive melanoma, tumor treatment by plasmid AMEPô biotherapy, applied through either intratumoral or intramuscular route, induced a strong tumor growth inhibition (>95% and >50% respectively). Moreover, preliminary acute toxicology studies show that plasmid AMEPô biotherapy is safe and well-tolerated.
Preclinical toxicology and biodistribution regulatory studies are in progress and will allow the submission of the regulatory file for a phase I clinical trial planned in 2009 in metastatic melanoma patients.
About the American Association of Cancer Research (AACR)
The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.
About BioAlliance Pharma SA
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharmaís ambition is to become a leading player in these fields by coupling innovation to patient needs.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).
For more information, please click here
BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59
Copyright © Business Wire 2009If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017
Leti Presents Advances in Propagation Modeling and Antenna Design for mmWave Spectrum: Paper Is One of 15 that Leti Presented at European Conference on Antennas and Propagation March 19-24 March 23rd, 2017
Next-gen steel under the microscope March 18th, 2017
UC researchers use gold coating to control luminescence of nanowires: University of Cincinnati physicists manipulate nanowire semiconductors in pursuit of making electronics smaller, faster and cheaper March 17th, 2017